Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
IHC 1+ and Greater
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
- NCT05911295 ↗
- Active, not recruiting
- Seagen, a wholly owned subsidiary of Pfizer
- Focused
We haven't built an HCP commentary report on IHC 1+ and Greater (disitamab vedotin, pembrolizumab and 3 more in Urothelial Carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on IHC 1+ and Greater so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 6 | |
| YouTube | 2 |
The trial
ClinicalTrials.gov- Official title
- An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination With Pembrolizumab Versus Chemotherapy in Subjects With Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma That Expresses HER2 (IHC 1+ and Greater)
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Urothelial Carcinoma
- Interventions
- disitamab vedotin; pembrolizumab; gemcitabine; cisplatin; carboplatin
- Arms
- Disitamab vedotin arm · Experimental
- Standard of care arm · Active comparator
- Enrollment
- 412
- Primary outcomes
- Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) by blinded independent central review (BICR)
- Overall survival (OS)
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer with RemeGen Co., Ltd., Merck Sharp & Dohme LLC
- Start
- Sep 22, 2023
- Primary completion
- Jan 29, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05911295 · updated Jul 22, 2026